Recent Updates
Recently added Catalysts
OBX Positive Sentiment

Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Monday, June 2, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Obsidian Therapeutics presented positive Phase 1 clinical data for OBX-115 at the 2025 ASCO Annual Meeting. The study involved 11 patients with advanced melanoma who were resistant to immune checkpoint inhibitors. The novel therapy, which utilizes engineered TIL cells, achieved an overall response rate of 67%.

Market Sentiment Analysis

POSITIVE FACTORS

  • OBX-115 demonstrated a 67% overall response rate (ORR).
  • The therapy is designed for patients resistant to immune checkpoint inhibitors.
  • The results were presented at a prestigious conference, ASCO.

Full Press Release Details

Oral presentation of Phase 1 results from Agni-01 multicenter study of cryopreserved OBX-115, a novel IL2-sparing engineered TIL cell therapy armored with pharmacologically regulatable membrane-bound IL15 (mbIL15), in patients with ICI-resistant advanced melanoma (n=11) OBX-115 ORR was 67% at

Frequently Asked Questions

What is OBX-115?

OBX-115 is a novel IL2-sparing engineered TIL cell therapy for melanoma.

What were the results of the OBX-115 study?

The study reported a 67% overall response rate in patients with advanced melanoma.

Where was the OBX-115 data presented?

The data was presented at the 2025 American Society of Clinical Oncology meeting.

Who were the patients in the OBX-115 study?

Patients in the study were those with ICI-resistant advanced melanoma.

ShareAdd on Google
Tags: OBX Obsidian Therapeutics OBX-115 advanced melanoma ASCO 2025 IL2-sparing therapy
Last updated: Jun 2, 2025

Biotech snapshot

Cash runway
$0M liquidity · $0M/mo burn
Low dilution risk